Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Solid Tumor: early-phase trial registry
37 of 53 indexed Metastatic Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #265 of 28,707 conditions by registered trial count.
53 US clinical trials · 37 currently recruiting · #265 of 28,707 conditions by registered trial count
Metastatic Solid Tumor: 53 US clinical trials tracked, 37 recruiting.
Metastatic Solid Tumor is the subject of 53 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 50 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 4 of these trials.
Enrollment posture brief
Registry condition metastatic-solid-tumor
OPEN 37 | RECR 70% | LATE 0 | EARLY 50 | RANK #265 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Metastatic Solid Tumor lists 37 open slots (70% of 53 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Solid Tumor is recruiting above its size-band peers.
37 of 53 indexed trials (69.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Solid Tumor trials is spread across many organizations.
Eli Lilly and Company accounts for 4 of 53 trials (7.5%). 43 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Solid Tumor enrolment sits around 130 participants.
Median target enrolment is 130 among the 53 trials that report a genuine target (sentinel values excluded). 22 of those (41.5%) plan for fewer than 100 participants.
-
Metastatic Solid Tumor research is mostly interventional.
51 interventional and 2 observational studies make up this index (96.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
53 total, page 1 of 2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent
NCT05384626
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT05875168
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
NCT04137900
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Frontier Medicines Corporation
NCT06244771
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Nuvalent
NCT05118789
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation
NCT05824975
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06561685
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
GI Innovation
NCT04977453
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06545942
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent
NCT06521554
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT06108050
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma
NCT05933265
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium
NCT07284186
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology
NCT06657144
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Biocity Biopharmaceutics Co.
NCT06548672
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06974110
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
NCT05856981
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
NCT07213817
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
NCT07213830
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co.
NCT06266299
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics
NCT06171750
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics
NCT06778863
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeiGene
NCT06803680
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex
NCT06440005
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05004116
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
NCT06952010
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Valley Health System
NCT05232409
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
NCT06302621
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
SOTIO Biotech
NCT06163391
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
M.D. Anderson Cancer Center
NCT05673928
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Acepodia Biotech
NCT06415487
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
University of Utah
NCT06358677
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
NCT05694715
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT06607185
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT05081609
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Gilead Sciences
NCT03964727
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Artios Pharma
NCT05898399
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics
NCT05479812
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals
NCT04892017
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Triumvira Immunologics
NCT05862324
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
NCT05863052
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05678010
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio
NCT04898543
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Immunophotonics
NCT05688280
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT04419532
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Tachyon Therapeutics
NCT05076552
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Solid Tumor page
53 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Metastatic Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Metastatic Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Solid Tumor condition card totals 53 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.